---

---

for   tags : Product-news   

save search

---

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.185 0.19% 430K |

Health Technology

| -7.07% | O: 1.84% H: 0.24% C: -0.14%
adzynma japan takeda approval injection

---

BD Increases Domestic Production to Support U.S. Health Care Need for Syringes
Published: 2024-03-21 (Crawled : 12:00) - biospace.com/
BDX | $235.01 0.8% 330K |

Health Technology

| -2.88% | O: 0.46% H: 1.26% C: 1.11%
health care

---

Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®
Published: 2024-02-29 (Crawled : 17:00) - biospace.com/
JNJ | News | $147.17 0.98% 3.2M |

Health Technology

| -10.02% | O: 0.56% H: 0.12% C: -0.38%
stelara biosimilar market

---

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-02-19 (Crawled : 09:00) - biospace.com/
AZN | $68.3 -0.09% 2M |

Health Technology

| Email alert Add to watchlist
lung license cancer cell application advanced

---

InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program
Published: 2024-01-22 (Crawled : 07:00) - biospace.com/
XNCR | $18.325 -3.3% 220K |

Health Technology

| -2.9% | O: 0.56% H: 1.97% C: 1.37%
MOR | $17.96 -0.5% 72K |

Health Technology

| 96.84% | O: 0.11% H: 1.96% C: -0.27%
first bay program

---

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Published: 2024-01-17 (Crawled : 14:30) - biospace.com/
XBIO | $4.14 100 |

Health Technology

| 5.46% | O: 0.0% H: 0.0% C: -4.37%
research agreement platform

---

LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC
Published: 2023-12-26 (Crawled : 06:00) - biospace.com/
JNJ | News | $147.17 0.98% 3.2M |

Health Technology

| -6.6% | O: -0.16% H: 0.0% C: 0.0%
lcb84 license agreement

---

Thermo Fisher Scientific Announces Launch of Innovative CorEvitas Pharmacovigilance Platform for Clinical Research Registries
Published: 2023-12-20 (Crawled : 14:00) - biospace.com/
TMO | News | $544.01 0.46% 470K |

Health Technology

| 2.18% | O: 1.22% H: 0.85% C: -1.62%
research platform

---

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
Published: 2023-12-08 (Crawled : 21:00) - biospace.com/
PFE A | $25.81 1.65% 15M |

Health Technology

| -11.21% | O: 0.07% H: 1.1% C: 0.45%
elrexfio

---

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry DiseasePatient enrollment expected to begin in first half of 2024
Published: 2023-11-29 (Crawled : 14:30) - biospace.com/
QURE | $4.65 -1.27% 180K |

Health Technology

| -32.52% | O: 0.0% H: 4.58% C: -2.58%
amt-191 fda drug expected clearance application therapy

---

Masimo W1™ Medical Watch Receives FDA 510(k) Clearance for Over-the-Counter and Prescription Use
Published: 2023-11-17 (Crawled : 22:00) - biospace.com/
MASI | $135.68 -0.18% 56K |

Health Technology

| 46.81% | O: 0.09% H: 1.29% C: 0.7%
fda clearance medical

---

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2023-11-17 (Crawled : 16:00) - biospace.com/
BGNE | $129.995 -1.49% 110K |

Health Technology

| -29.14% | O: 0.0% H: 0.38% C: -1.21%
brukinsa approval treatment

---

Vertex & CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Published: 2023-11-16 (Crawled : 10:00) - biospace.com/
VRTX | News | $395.0 0.39% 550K |

Health Technology

| 13.06% | O: 0.4% H: 0.38% C: -2.2%
CRSP M | $54.78 -2.46% 800K |

Health Technology

| 3.08% | O: 3.25% H: 4.05% C: 2.0%
crispr disease authorization cell treatment therapeutics

---

Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
Published: 2023-10-18 (Crawled : 12:00) - biospace.com/
SAGE | $13.3 2.03% 500K |

Health Technology

| -36.0% | O: 0.87% H: 1.61% C: -3.0%
sage-718 drug disease granted food treatment designation therapeutics

---

Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC
Published: 2023-10-13 (Crawled : 12:00) - biospace.com/
NUVL | $63.97 1.44% 77K |

| 6.89% | O: -0.68% H: 0.09% C: -2.86%
nvl-655 trial potential

---

Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
Published: 2023-10-03 (Crawled : 12:30) - biospace.com/
URGN | $14.03 -1.61% 170K |

Health Technology

| 4.67% | O: 1.83% H: 4.16% C: -0.5%
ugn-102 meeting submission

---

Angle PLC Announces Parsortix Outperforms Standard for DTC Harvest
Published: 2023-10-03 (Crawled : 09:00) - biospace.com/
ANPCF | $0.148 641.22% 5K |

Health Technology

| Email alert Add to watchlist
ANPCY | $1.98 338.38% 930 |

Manufacturing

| Email alert Add to watchlist
harvest

---

Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients
Published: 2023-09-28 (Crawled : 07:00) - biospace.com/
INVA | $14.94 1.7% 180K |

Health Technology

| 9.95% | O: -0.08% H: 0.99% C: 0.53%
xerava approval treatment infections

---

NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
Published: 2023-09-27 (Crawled : 13:00) - biospace.com/
NAOV 4 | $0.75 20K |

Health Technology

| -66.52% | O: -5.8% H: 12.8% C: 6.16%
drug approval uroshield

---

European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
Published: 2023-09-19 (Crawled : 09:00) - biospace.com/
PFE A | $25.81 1.65% 15M |

Health Technology

| -24.44% | O: -0.27% H: 1.37% C: 1.31%

---

Gainers vs Losers

74%

26%

Top 10 Gainers

AGBA | News | $1.27 217.5% 120M |

Finance

EGOX | $0.054 50.0% 290M |

INDO | $5.43 33.09% 10M |

Energy Minerals

NVFY | $2.71 28.44% 31M |

Consumer Durables

ZCMD | $1.86 28.28% 29M |

Commercial Services

BSFC | $0.0822 27.64% 75M |

Manufacturing

RWOD | $10.08 26.05% 5.6M |

n/a

CHRO | $1.53 24.9% 100K |

n/a

HUSA 4 | $2.07 23.95% 2.1M |

Energy Minerals

INSG | $2.98 23.14% 190K |

Electronic Technology

---

Your saved searches

---